IBDEI0Z8 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,15903,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15903,1,3,0)
;;=3^Acrodermatitis Continua
;;^UTILITY(U,$J,358.3,15903,1,4,0)
;;=4^L40.2
;;^UTILITY(U,$J,358.3,15903,2)
;;=^5009162
;;^UTILITY(U,$J,358.3,15904,0)
;;=L40.3^^61^765^295
;;^UTILITY(U,$J,358.3,15904,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15904,1,3,0)
;;=3^Pustulosis Palmaris et Plantaris
;;^UTILITY(U,$J,358.3,15904,1,4,0)
;;=4^L40.3
;;^UTILITY(U,$J,358.3,15904,2)
;;=^5009163
;;^UTILITY(U,$J,358.3,15905,0)
;;=L40.4^^61^765^160
;;^UTILITY(U,$J,358.3,15905,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15905,1,3,0)
;;=3^Guttate Psoriasis
;;^UTILITY(U,$J,358.3,15905,1,4,0)
;;=4^L40.4
;;^UTILITY(U,$J,358.3,15905,2)
;;=^5009164
;;^UTILITY(U,$J,358.3,15906,0)
;;=L40.8^^61^765^292
;;^UTILITY(U,$J,358.3,15906,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15906,1,3,0)
;;=3^Psoriasis NEC
;;^UTILITY(U,$J,358.3,15906,1,4,0)
;;=4^L40.8
;;^UTILITY(U,$J,358.3,15906,2)
;;=^271917
;;^UTILITY(U,$J,358.3,15907,0)
;;=L40.9^^61^765^294
;;^UTILITY(U,$J,358.3,15907,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15907,1,3,0)
;;=3^Psoriasis,Unspec
;;^UTILITY(U,$J,358.3,15907,1,4,0)
;;=4^L40.9
;;^UTILITY(U,$J,358.3,15907,2)
;;=^5009171
;;^UTILITY(U,$J,358.3,15908,0)
;;=L50.9^^61^765^326
;;^UTILITY(U,$J,358.3,15908,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15908,1,3,0)
;;=3^Urticaria,Unspec
;;^UTILITY(U,$J,358.3,15908,1,4,0)
;;=4^L50.9
;;^UTILITY(U,$J,358.3,15908,2)
;;=^5009204
;;^UTILITY(U,$J,358.3,15909,0)
;;=L53.8^^61^765^150
;;^UTILITY(U,$J,358.3,15909,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15909,1,3,0)
;;=3^Erythematous Conditions NEC
;;^UTILITY(U,$J,358.3,15909,1,4,0)
;;=4^L53.8
;;^UTILITY(U,$J,358.3,15909,2)
;;=^88044
;;^UTILITY(U,$J,358.3,15910,0)
;;=L53.9^^61^765^149
;;^UTILITY(U,$J,358.3,15910,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15910,1,3,0)
;;=3^Erythematous Condition,Unspec
;;^UTILITY(U,$J,358.3,15910,1,4,0)
;;=4^L53.9
;;^UTILITY(U,$J,358.3,15910,2)
;;=^5009210
;;^UTILITY(U,$J,358.3,15911,0)
;;=L54.^^61^765^148
;;^UTILITY(U,$J,358.3,15911,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15911,1,3,0)
;;=3^Erythema in Diseases Classified Elsewhere
;;^UTILITY(U,$J,358.3,15911,1,4,0)
;;=4^L54.
;;^UTILITY(U,$J,358.3,15911,2)
;;=^5009211
;;^UTILITY(U,$J,358.3,15912,0)
;;=L56.0^^61^765^142
;;^UTILITY(U,$J,358.3,15912,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15912,1,3,0)
;;=3^Drug Phototoxic Response
;;^UTILITY(U,$J,358.3,15912,1,4,0)
;;=4^L56.0
;;^UTILITY(U,$J,358.3,15912,2)
;;=^5009214
;;^UTILITY(U,$J,358.3,15913,0)
;;=L56.1^^61^765^141
;;^UTILITY(U,$J,358.3,15913,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15913,1,3,0)
;;=3^Drug Photoallergic Response
;;^UTILITY(U,$J,358.3,15913,1,4,0)
;;=4^L56.1
;;^UTILITY(U,$J,358.3,15913,2)
;;=^5009215
;;^UTILITY(U,$J,358.3,15914,0)
;;=L56.2^^61^765^274
;;^UTILITY(U,$J,358.3,15914,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15914,1,3,0)
;;=3^Photocontact Dermatitis
;;^UTILITY(U,$J,358.3,15914,1,4,0)
;;=4^L56.2
;;^UTILITY(U,$J,358.3,15914,2)
;;=^5009216
;;^UTILITY(U,$J,358.3,15915,0)
;;=L56.3^^61^765^308
;;^UTILITY(U,$J,358.3,15915,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15915,1,3,0)
;;=3^Solar Urticaria
;;^UTILITY(U,$J,358.3,15915,1,4,0)
;;=4^L56.3
;;^UTILITY(U,$J,358.3,15915,2)
;;=^5009217
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0Z8 3774 printed Dec 13, 2024@01:58:39 Page 2
IBDEI0Z8 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,15903,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,15903,1,3,0)
+4 ;;=3^Acrodermatitis Continua
+5 ;;^UTILITY(U,$J,358.3,15903,1,4,0)
+6 ;;=4^L40.2
+7 ;;^UTILITY(U,$J,358.3,15903,2)
+8 ;;=^5009162
+9 ;;^UTILITY(U,$J,358.3,15904,0)
+10 ;;=L40.3^^61^765^295
+11 ;;^UTILITY(U,$J,358.3,15904,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,15904,1,3,0)
+14 ;;=3^Pustulosis Palmaris et Plantaris
+15 ;;^UTILITY(U,$J,358.3,15904,1,4,0)
+16 ;;=4^L40.3
+17 ;;^UTILITY(U,$J,358.3,15904,2)
+18 ;;=^5009163
+19 ;;^UTILITY(U,$J,358.3,15905,0)
+20 ;;=L40.4^^61^765^160
+21 ;;^UTILITY(U,$J,358.3,15905,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,15905,1,3,0)
+24 ;;=3^Guttate Psoriasis
+25 ;;^UTILITY(U,$J,358.3,15905,1,4,0)
+26 ;;=4^L40.4
+27 ;;^UTILITY(U,$J,358.3,15905,2)
+28 ;;=^5009164
+29 ;;^UTILITY(U,$J,358.3,15906,0)
+30 ;;=L40.8^^61^765^292
+31 ;;^UTILITY(U,$J,358.3,15906,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,15906,1,3,0)
+34 ;;=3^Psoriasis NEC
+35 ;;^UTILITY(U,$J,358.3,15906,1,4,0)
+36 ;;=4^L40.8
+37 ;;^UTILITY(U,$J,358.3,15906,2)
+38 ;;=^271917
+39 ;;^UTILITY(U,$J,358.3,15907,0)
+40 ;;=L40.9^^61^765^294
+41 ;;^UTILITY(U,$J,358.3,15907,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,15907,1,3,0)
+44 ;;=3^Psoriasis,Unspec
+45 ;;^UTILITY(U,$J,358.3,15907,1,4,0)
+46 ;;=4^L40.9
+47 ;;^UTILITY(U,$J,358.3,15907,2)
+48 ;;=^5009171
+49 ;;^UTILITY(U,$J,358.3,15908,0)
+50 ;;=L50.9^^61^765^326
+51 ;;^UTILITY(U,$J,358.3,15908,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,15908,1,3,0)
+54 ;;=3^Urticaria,Unspec
+55 ;;^UTILITY(U,$J,358.3,15908,1,4,0)
+56 ;;=4^L50.9
+57 ;;^UTILITY(U,$J,358.3,15908,2)
+58 ;;=^5009204
+59 ;;^UTILITY(U,$J,358.3,15909,0)
+60 ;;=L53.8^^61^765^150
+61 ;;^UTILITY(U,$J,358.3,15909,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,15909,1,3,0)
+64 ;;=3^Erythematous Conditions NEC
+65 ;;^UTILITY(U,$J,358.3,15909,1,4,0)
+66 ;;=4^L53.8
+67 ;;^UTILITY(U,$J,358.3,15909,2)
+68 ;;=^88044
+69 ;;^UTILITY(U,$J,358.3,15910,0)
+70 ;;=L53.9^^61^765^149
+71 ;;^UTILITY(U,$J,358.3,15910,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,15910,1,3,0)
+74 ;;=3^Erythematous Condition,Unspec
+75 ;;^UTILITY(U,$J,358.3,15910,1,4,0)
+76 ;;=4^L53.9
+77 ;;^UTILITY(U,$J,358.3,15910,2)
+78 ;;=^5009210
+79 ;;^UTILITY(U,$J,358.3,15911,0)
+80 ;;=L54.^^61^765^148
+81 ;;^UTILITY(U,$J,358.3,15911,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,15911,1,3,0)
+84 ;;=3^Erythema in Diseases Classified Elsewhere
+85 ;;^UTILITY(U,$J,358.3,15911,1,4,0)
+86 ;;=4^L54.
+87 ;;^UTILITY(U,$J,358.3,15911,2)
+88 ;;=^5009211
+89 ;;^UTILITY(U,$J,358.3,15912,0)
+90 ;;=L56.0^^61^765^142
+91 ;;^UTILITY(U,$J,358.3,15912,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,15912,1,3,0)
+94 ;;=3^Drug Phototoxic Response
+95 ;;^UTILITY(U,$J,358.3,15912,1,4,0)
+96 ;;=4^L56.0
+97 ;;^UTILITY(U,$J,358.3,15912,2)
+98 ;;=^5009214
+99 ;;^UTILITY(U,$J,358.3,15913,0)
+100 ;;=L56.1^^61^765^141
+101 ;;^UTILITY(U,$J,358.3,15913,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,15913,1,3,0)
+104 ;;=3^Drug Photoallergic Response
+105 ;;^UTILITY(U,$J,358.3,15913,1,4,0)
+106 ;;=4^L56.1
+107 ;;^UTILITY(U,$J,358.3,15913,2)
+108 ;;=^5009215
+109 ;;^UTILITY(U,$J,358.3,15914,0)
+110 ;;=L56.2^^61^765^274
+111 ;;^UTILITY(U,$J,358.3,15914,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,15914,1,3,0)
+114 ;;=3^Photocontact Dermatitis
+115 ;;^UTILITY(U,$J,358.3,15914,1,4,0)
+116 ;;=4^L56.2
+117 ;;^UTILITY(U,$J,358.3,15914,2)
+118 ;;=^5009216
+119 ;;^UTILITY(U,$J,358.3,15915,0)
+120 ;;=L56.3^^61^765^308
+121 ;;^UTILITY(U,$J,358.3,15915,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,15915,1,3,0)
+124 ;;=3^Solar Urticaria
+125 ;;^UTILITY(U,$J,358.3,15915,1,4,0)
+126 ;;=4^L56.3
+127 ;;^UTILITY(U,$J,358.3,15915,2)
+128 ;;=^5009217
